clinical trial · NCT05875168
First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors
Daiichi Sankyo·phase2·recruiting·n = 540
Advanced Solid TumorMetastatic Solid TumorDS-3939a
brief summary
This study will evaluate the safety, tolerability, and efficacy of DS-3939a in participants with advanced solid tumors.
started
Aug 18, 2023
primary completion
Oct 20, 2026
completion
Feb 15, 2027
last updated
Apr 20, 2026
detailed description
DS-3939a is an antibody drug conjugate (ADC) being developed for the treatment of malignant tumors. This is a first-in-human, dose-escalating clinical study divided into 2 parts: the Dose Escalation Part (Part 1) and the Dose Expansion Part (Part 2).
official title
Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol